

# Alessandra Leone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2898465/publications.pdf>

Version: 2024-02-01

37  
papers

1,473  
citations

331670

21  
h-index

414414

32  
g-index

38  
all docs

38  
docs citations

38  
times ranked

2972  
citing authors

#	ARTICLE	IF	CITATIONS
1	HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 83.	8.6	19
2	Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	25
3	Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2118475.	5.9	16
4	Large extracellular vesicles: Size matters in tumor progression. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 69-74.	7.2	41
5	Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 213.	8.6	26
6	Targeting Autophagy in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7836.	4.1	54
7	Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i> -mutated metastatic colorectal cancer: the REVOLUTION study protocol. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092958.	3.2	10
8	Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 732.	3.7	22
9	Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 317.	8.6	82
10	Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1405-1417.	4.1	18
11	A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. <i>Scientific Reports</i> , 2018, 8, 5823.	3.3	38
12	The Crosstalk between Cancer Stem Cells and Microenvironment Is Critical for Solid Tumor Progression: The Significant Contribution of Extracellular Vesicles. <i>Stem Cells International</i> , 2018, 2018, 1-11.	2.5	31
13	Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-18.	4.0	102
14	Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 177.	8.6	33
15	Management of non-small cell lung cancer in the era of personalized medicine. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 78, 173-179.	2.8	25
16	A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization) Tj ETQq0 00gBT /Overlock 10		
17	Endothelial progenitor cells, defined by the simultaneous surface expression of <i>VEGFR</i> 2 and <i>CD</i> 133, are not detectable in healthy peripheral and cord blood. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 259-270.	1.5	51
18	Enhancement of 5-FU sensitivity by the proapoptotic rpl3 gene in p53 null colon cancer cells through combined polymer nanoparticles. <i>Oncotarget</i> , 2016, 7, 79670-79687.	1.8	44

#	ARTICLE	IF	CITATIONS
19	Valproic acid potentiates the anticancer activity of capecitabine <i>in vitro</i> and <i>in vivo</i> in breast cancer models via induction of thymidine phosphorylase expression. <i>Oncotarget</i> , 2016, 7, 7715-7731.	1.8	67
20	Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. <i>Oncotarget</i> , 2016, 7, 19559-19574.	1.8	20
21	Abstract 4745: Repurposing of valproic acid and simvastatin combination as anticancer agents in prostate cancer: synergistic interaction with docetaxel and suppression of docetaxel resistance. , 2016, , .		0
22	Phenolic compounds and quality parameters of family farming versus protected designation of origin (PDO) extra-virgin olive oils. <i>Journal of Food Composition and Analysis</i> , 2015, 43, 75-81.	3.9	45
23	Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. <i>Free Radical Biology and Medicine</i> , 2015, 89, 287-299.	2.9	73
24	Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trial. <i>Oncotarget</i> , 2015, 6, 30394-30407.	1.8	44
25	Abstract 2569: Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer as a rationale for the innovative V-shoRT-R3 trial in locally advanced rectal cancer patients. , 2015, , .		0
26	New Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent. <i>Cancer Treatment and Research</i> , 2014, 159, 355-376.	0.5	119
27	Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15. <i>Cancer Research</i> , 2014, 74, 3408-3417.	0.9	101
28	Abstract 5444: Modulation of ErbB receptors expression by histone deacetylase inhibitors increased the antitumor activity of an anti-ErbB3 monoclonal antibody in primary cultures from non-small cell lung cancer patients. , 2014, , .		0
29	Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. <i>Cell Death and Disease</i> , 2013, 4, e641-e641.	6.3	57
30	Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. <i>Cell Death and Disease</i> , 2013, 4, e878-e878.	6.3	50
31	Multidisciplinary Approach to Rectal Cancer: Are we Ready for Selective Treatment Strategies?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 852-860.	1.7	14
32	Abstract 4695: Predictive role of FDG PET-CT in monitoring locally advanced rectal cancer (LARC) during preoperative radiochemotherapy with an experimental bevacizumab schedule.. , 2013, , .		0
33	Abstract LB-219: Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: efficacy, safety, and biomarkers.. , 2012, , .		1
34	Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hepâ€2 cancer cells. <i>Proteomics</i> , 2011, 11, 3725-3742.	2.2	21
35	HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. <i>Journal of Cellular Physiology</i> , 2011, 226, 2378-2390.	4.1	139
36	Abstract 3721: Critical role of Bevacizumab schedule in combination with chemo-radiotherapy in neo-adjuvant treatment of rectal cancer: Circulating endothelial cells and FDG-PET as markers for early prediction. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
37	Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed. <i>Cancer Biology and Therapy</i> , 2009, 8, 782-791.	3.4	65